ارزیابی مقایسه‌ای تأثیر درمان نگهدارنده با متادون و بوپرنورفین بر عملکرد جنسی زنان وابسته به/سوءمصرف مواد اپیوئیدی (داروهای افیونی)

نوع مقاله : اصیل پژوهشی

نویسندگان

1 دستیار تخصصی روان‌پزشکی، مرکز تحقیقات علوم رفتاری و گروه روان‌پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران.

2 استاد گروه روا‌ن‌پزشکی، مرکز تحقیقات علوم رفتاری و گروه روان‌پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران.

3 دانشیار گروه اپیدمیولوژی و آمار زیستی، دانشکده بهداشت، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران.

4 استادیار پژوهشی، مرکز تحقیقات علوم رفتاری و گروه روان‌پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران.

5 کارشناس ارشد روانشناس بالینی، دانشکده علوم انسانی، دانشگاه آزاد اسلامی نجف‌آباد، ایران.

چکیده

مقدمه: اختلالات جنسی مرتبط با استفاده طولانی‌مدت از متادون و بوپرنورفین بسیار شایع هستند. به‌منظور بررسی تأثیرات درمان نگهدارنده با متادون (MMT) و بوپرنورفین (BMT) بر عملکرد جنسی زنانی که دچار وابستگی به سوء‌مصرف مواد اپیوئیدی هستند، مطالعه حاضر با هدف ارزیابی مقایسه‌ای تأثیر درمان نگهدارنده با استفاده از متادون و بوپرنورفین بر عملکرد جنسی زنان مبتلا به وابستگی به سوءمصرف مواد اپیوئیدی انجام شد تا اقدامات مؤثری جهت انتخاب بهتر در زمینه مشاوره و تصمیم‌گیری در خصوص درمان این افراد صورت گیرد.
روش‌کار: اینمطالعه توصیفی- تحلیلی مقطعی در سال 96-1394 بر روی 89 زن مبتلا به سوء‌مصرف مواد افیونی انجام شد. اطلاعات دموگرافیک، عملکرد جنسی و رضایت‌مندی زنانی که از قبل تحت درمان با MMT و BMT بودند، با استفاده از پرسشنامه‌های شاخص عملکرد جنسی زنان (FSFI) و رضایت جنسی لارسون در دو مقطع با فاصله 3 ماه تکمیل و جمع‌آوری گردید. تجزیه و تحلیل داده‌ها با استفاده از نرم‌افزار آماری SPSS (نسخه 20) و آزمون‌های تی مستقل، یومن‌ویتنی و کای اسکوئر انجام شد. میزان p کمتر از 05/0 معنی‌دار در نظر گرفته شد.
یافته‌ها: نمرات کل مقیاس (پرسشنامه شاخص عملکرد جنسی زنان) FSFI در گروه BMT به‌طور معنی‌داری بالاتر بود (05/0>p). نمرات حاصل از مقیاس میل جنسی و خرده مقیاس‌های برانگیختگی در گروه BMT نسبت به گروه MMT به‌طور معنی‌داری بهبود یافتند (05/0>p). از نظر سطح رضایت جنسی در دو مقطع مورد بررسی، بین دو گروه اختلاف معنی‌داری مشاهده نشد (25/0=p).
نتیجه‌گیری: استفاده از BMT در زنان مبتلا به سوء‌مصرف مواد اپیوئیدی می‌تواند تأثیر مثبت بیشتری نسبت به MMT در میل جنسی و برانگیختگی جنسی این افراد داشته باشد. این امر احتمالاً منجر به پیوستگی بیشتری به استفاده از درمان نگهدارنده می‌شود. در موارد دیگر، این دو دارو از لحاظ میزان اثربخشی و ایجاد رضایت‌مندی از عملکرد جنسی مشابه یکدیگر هستند.

کلیدواژه‌ها


عنوان مقاله [English]

The effect of maintenance treatment with methadone and buprenorphine on sexual function of females addicted to opiates

نویسندگان [English]

  • Farideh Sadat Ammozegar 1
  • Mehrdad Salehi 2
  • Mohammad Javad Tarrahi 3
  • Mitra Molaeinezhad 4
  • Fatemeh Moradinasab 5
1 Resident, Department of Psychiatry, Behavioral Sciences and Psychiatry Department Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2 Professor, Department of Psychiatry, Behavioral Sciences Research Center and Psychiatry Department, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
3 Associate Professor, Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Science, Isfahan, Iran.
4 Assistant Professor, Department of Research, Behavioral Sciences Research Center and Psychiatry Department, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
5 M.Sc. in Clinical Psychology, School of Human Sciences, Najafabad Islamic Azad University, NajafAbad, Iran.
چکیده [English]

Introduction: Sexual dysfunctions related to the long-term of methadone and buprenorphine are common. In order to investigate the effects of Methadone maintenance therapy (MMT) and buprenorphine maintenance treatment(BMT) on women sexual function with opioid abuse dependence, the present study was performed with aim to evaluate the effect ofmaintenance treatment with methadone and buprenorphine on sexual function of females with opioid abuse dependence .In order to the effective measures regarding choosing the best practice , consultation and decision making will be taken.
Methods: This cross-sectional descriptive-analytic study was performed in 2015-2017 on 89 women with opioid abuse. Demographic information, sexual function and satisfaction of women who were previously treated with MMT and BMT were completed and collected using the Female sexual function index(FSFI) and Larson Sexual satisfaction questionnaire (LSSQ) in two stages with an interval of 3 months. Data were analyzed by SPSS software (version 20) and Independent T, Mann-Whitney U and Chi-Square tests.
Results: The total scores of FSFI (Female Sexual Function Index) were significantly higher in the BMT group (p < 0.05). The scores of sexual desire and arousal subscales were significantly improved in the BMT group compared with the MMT group (p < 0.05). No significant difference was observed between the two groups in terms of the level of sexual satisfaction in two studied stages (p=0.25).
Conclusion: The use of BMT in women with opioid abuse can have a more positive effect on sexual desire and arousal than those in the MMT group. This issue likely leads to more adhesion to the use of maintenance treatment. In other cases, these two drugs are similar in terms of efficacy and causing satisfaction from sexual function.

کلیدواژه‌ها [English]

  • Dependence
  • Buprenorphine
  • methadone
  • Sexual dysfunction
  • Women
  1. Vasilev G, Milcheva S, Vassileva J. Opioid use in the twenty first century: similarities and differences across national borders. Current treatment options in psychiatry 2016; 3(3):293-305.
  2. Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2015.
  3. Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harvard review of psychiatry 2015; 23(2):76-89.
  4. Amato L, Davoli M, Ferri MM, Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2003; (2).
  5. Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, Teymoori-Rad M, Bont L, Shokri F, et al. Opioids and viral infections: a double-edged sword. Frontiers in microbiology 2016; 7:970.
  6. Grover S, Mattoo SK, Pendharkar S, Kandappan V. Sexual dysfunction in patients with alcohol and opioid dependence. Indian journal of psychological medicine 2014; 36(4):355-65.
  7. Ramdurg S, Ambekar A, Lal R. Co-relationship between sexual dysfunction and high-risk sexual behavior in patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence. Industrial psychiatry journal 2015; 24(1):29.
  8. Diehl A, Silva RL, Laranjeira R. Female sexual dysfunction in patients with sub-stance-related disorders. Clinics 2013; 68(2):205-12.
  9. Bonhomme J, Shim RS, Gooden R, Tysu D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. Journal of the National Medical Association 2012; 104(7-8):342-50.
  10. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. Journal of addictive diseases 2012; 31(3):207-25.
  11. Lenné M, Lintzeris N, Breen C, Harris S, Hawken L, Mattick R, et al. Withdrawal from methadone maintenance treatment: prognosis and participant perspectives. Australian and New Zealand journal of public health 2001; 25(2):121-5.
  12. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Archives of internal medicine 2006; 166(12):1280-7.
  13. George P, Vicknasingam B, Thurairajasingam S, Ramasamy P, Mohd Yusof H, Yasin MA, et al. Methadone complications amongst opioid‐dependent patients in Malaysia: A case series. Drug and alcohol review 2018; 37(1):147-51.
  14. Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: risk factors in pain and addicted populations. Journal of general internal medicine 2010; 25(4):305-9.
  15. Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O. A systematic review of the cardiotoxicity of methadone. EXCLI journal 2015; 14:577.
  16. Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Current neuropharmacology 2004; 2(4):395-402.
  17. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics 1994; 55(5):569-80.
  18. Fareed A, Patil D, Scheinberg K, Blackinton Gale R, Vayalapalli S, Casarella J, et al. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. Journal of addictive diseases 2013; 32(3):244-51.
  19. Gray A. Systematic review of the safety of buprenorphine methadone and naltrexone. Department of Therapeutics and Medicines Center for the AIDS Programme of Research in South Africa Congella, South Africa 2007.
  20. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database of systematic reviews 2014(2).
  21. Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. Journal of addiction medicine 2015; 9(2):81-6.
  22. Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Mokri A. The establishment of a methadone treatment clinic for women in Tehran, Iran. Journal of Public Health Policy 2011; 32(2):219-30.
  23. Bahrami N, Sharif Nia H, Soliemani MA, Haghdoost AA. Validity and reliability of the persian version of Larson sexual satisfaction questionnaire in couples. Journal of Kerman University of Medical Sciences 2016; 23(3):344-56.
  24. Rosen C, Brown J, Heiman S, Leiblum C, Meston R, Shabsigh D, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Journal of sex & marital therapy 2000; 26(2):191-208.
  25. Heydari M, Faghihzadeh S. The female sexual function index (FSFI): validation of the Iranian version. Payesh (Health Monitor) 2008; 7(3).
  26. Varma A, Sethi R, Hartman DW, Herbertson R, Kablinger AS. Sexual Functioning and Quality of Life of Women with Opioid Dependence Maintained on Buprenorphine/Naloxone vs Community Norms. J Subst Abuse Alcohol 2014; 2(1):1005.
  27. Yee A, Danaee M, Loh HS, Sulaiman AH, Ng CG. Sexual dysfunction in heroin dependents: a comparison between methadone and buprenorphine maintenance treatment. PloS one 2016; 11(1):e0147852.
  28. Brown RT, Zueldorff M. Opioid substitution with methadone and buprenorphine: sexual dysfunction as a side effect of therapy. Heroin Addict Relat Clin Probl 2007; 9(1):35-44.
  29. Xia Y, Zhang D, Li X, Chen W, He Q, Jahn HJ, et al. Sexual dysfunction during methadone maintenance treatment and its influence on patient's life and treatment: A qualitative study in South China. Psychology, health & medicine 2013; 18(3):321-9.
  30. Curcio F, Franco T, Topa M, Baldassarre C, Responsabili G. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Eur Rev Med Pharmacol Sci 2011; 15(8):871-4.
  31. Kopetz CE, Reynolds EK, Hart CL, Kruglanski AW, Lejuez CW. Social context and perceived effects of drugs on sexual behavior among individuals who use both heroin and cocaine. Experimental and Clinical Psychopharmacology 2010; 18(3):214.
  32. Kheradmand A, Banazadeh N, Abedi H. Physical effects of methadone maintenance treatment from the standpoint of clients. Addiction & health 2010; 2(3-4):66.
  33. Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. The journal of sexual medicine 2008; 5(3):684-92.
  34. Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. Journal of addictive diseases 2005; 24(2):91-106.
  35. Shams MZ, Shahsiah M, Mohebi S, Tabaraee Y. The effect of marital counseling on sexual satisfaction of couples in Shiraz city. Health System Research 2010; 6(3):417-24.
  36. Student RA, Student AL. Relationship between sexual pleasure and marital satisfaction. Iran Journal of Nursing 2011; 24(70):82-90.
  37. Mendelson JH, Ellingboe JA, Mello NK, Kuehnle JO. Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. Journal of Pharmacology and Experimental Therapeutics 1982; 220(2):252-5.
  38. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. The Journal of Clinical Endocrinology & Metabolism 2005; 90(1):203-6.
  39. Singh HH, Purohit V, Ahluwalia BS. Methadone blocks dopamine-mediated release of gonadotropins in rat hypothalamus. Neuroendocrinology 1982; 34(5):347-52.
  40. Spasovska Trajanovska A, Vujovic V, Ignjatova L, Janikevik Ivanovska D, Chibishev A. Sexual dysfunction as a side effect of hyperprolactinemia in methadone maintenance therapy. Medical archives 2013; 67(1):48-50.
  41. AlAwlaqi A, Amor H, Hammadeh ME. Role of hormones in hypoactive sexual desire disorder and current treatment. Journal of the Turkish German Gynecological Association 2017; 18(4):210.
  42. Cappelletti M, Wallen K. Increasing women's sexual desire: the comparative effectiveness of estrogens and androgens. Hormones and behavior 2016; 78:178-93.
  43. Quaglio G, Lugoboni F, Pattaro C, Melara B, Mezzelani P, Des Jarlais DC. Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug and alcohol dependence 2008; 94(1-3):12-8.
  44. Bawor M, Dennis BB, Samaan MC, Plater C, Worster A, Varenbut M, et al. Methadone induces testosterone suppression in patients with opioid addiction. Sci Rep 2014; 4:6189.
  45. Babakhanian M, Haghdoost AA, Afshari M, Taghizadeh F, Moosazadeh M. Methadone replacement therapy and sexual disorders among opium dependent iranian men: a meta-analysis study. Addiction & health 2017; 9(1):1-10.
  46. Pfaus JG. Reviews: Pathways of sexual desire. The journal of sexual medicine 2009; 6(6):1506-33.
  47. Khajedaluee M, Dadgar Moghadam M. Maternal substance abuse and the child's addiction during adolescence and young adulthood. Iran J Obstet Gynecol Infertil 2013; 16(52):1-7.
  48. Salehi M, Barekatain M, Faghani F, Karimian N, Molaeinezhad M, Asadalloahi GA, et al. Bupropion efficacy on sexual dysfunction among male patients on methadone maintenance therapy: a double-blind placebo-controlled trial. Sexual and Relationship Therapy 2015; 30(3):364-75.